Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Grace Lu-Yao and colleagues have posted an interesting “Beyond the Abstract” commentary on the UroToday web site in relation to recent data about the associations between obesity and prostate cancer in America.
Filed under: Diagnosis, Risk | Tagged: biopsy, BMI, body mass index, obesity, risk | 2 Comments »
In this weekend’s prostate cancer news reports, we have addressed recent publications on: A SNP that may be specifically linked to risk for prostate cancer in African Americans The need for extended biopsies in men with larger prostates who are considering focal treatment for prostate cancer A possible association between diabetes, race, obesity, and risk [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: African American, age, biopsy, brachytherapy, diabetes, focal, hormone therapy, mortality, neoadjuvant, obesity, race, single nucleotide polymorphism, SNP, Treatment | Leave a Comment »
Some prior studies have suggested a relationship between obesity and adverse pathologic features on prostate biopsy and have suggested that obese patients may be at higher risk for prostate cancer-related death after radical prostatectomy. However, other studies have been unable to demonstrate any relationship between obesity and clinical risks from prostate cancer.
Filed under: Diagnosis, Risk | Tagged: obesity, risk, saturation biopsy | 1 Comment »
In today’s news reports we comment on: The possible link between obesity and prostate cancer risk The economic impact of widespread prostate cancer screening in Europe The potential roles of tumor volume and PSMs in projecting need for adjuvant radiotherapy post-surgery Biochemical progression after treatment with degarelix (at up to 1 year)
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: adiponectin, adjuvant radiation, biochemical failure, cost, Degarelix, obesity, positive surgical margin, risk, tumor volume | Leave a Comment »
Three reports discussed today address the refinement of risk information in the diagnosis and prognosis of prostate cancer, with specific regard to: Whether PSA levels should be adjusted based on BMI The prediction of Gleason score upstaging after surgery Tumor volume and percent cancer as predictors of prostate cancer progression post-surgery
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: BMI, Gleason score, obesity, percent cancer, PSA, tunor volume, upstaging | Leave a Comment »
A new analysis of data from the Shared Equal Access Regional Cancer Hospital (SEARCH) prostate cancer database has suggested that obese men with prostate cancer are at particularly high risk for recurrence of their disease — regardless of race.
Filed under: Living with Prostate Cancer | Tagged: obesity, recurrence, risk | Leave a Comment »
In today’s news reports we comment on studies dealing with: PSA level, body mass index, risk, and outcomes External beam radiotherapy in treatment of Japanese patients An endorectal balloon to prevent anal/rectal side effects of radiation? The optimal period of neoadjuvant hormone therapy prior to radiation therapy
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: BMI, body mass index, EBRT, endorectal balloon, external beam radiation, neoadjuvant hormone therapy, obesity, PSA | Leave a Comment »
In today’s news reports you will find items on: Obesity and PSA levels Outcomes after external beam radiation therapy Mitoxantrone + predisone after taxotere failure
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: EBRT, external beam radiation therapy, mitoxantrone, obesity, outcome, prednisone, PSA level | Leave a Comment »
In today’s news reports we cover items on: Prediction of risk for prostate cancer under-grading based on biopsy data The obesity/risk equation in prostate cancer Capecitabine + docetaxel in metastatic CRPC
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: biopsy, capecitabine, CRPC, docetaxel, Gleason score, obesity, risk, under-grading | Leave a Comment »
An interesting study from researchers in Seattle has proposed that the increasing prevalence of obesity in the USA since 1980 has partially obscured declines in prostate cancer mortality.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: mortality, obesity, risk | 4 Comments »
As reported by Reuters Health earlier today, the majority of men with early-stage, low- or moderate-grade prostate cancer do not, in fact die from this disease. This topic has been carefully addressed by a recent article in the January issue of the Journal of the American Geriatric Society. Prevention and management of other health conditions [...]
Filed under: Living with Prostate Cancer, Management | Tagged: cardiovascular risk, diabetes, mortality, obesity, survival | Leave a Comment »
Reports summarized today include one on the potential of “dynamic contrast-enhanced” magnetic resonance imaging (DCE-MRI) and a second on the impact of obesity on risk for prostate cancer detection.
Filed under: Diagnosis, Management, Risk | Tagged: dynamic contrast-enhanced, MRI, obesity, risk | Leave a Comment »
Today’s inauguration day (here in the USA) news reports address: Obesity and prostate cancer screening PSA levels The possible association of bone mineral density with prostate cancer risk in older men Soy, genistein, and the inhibition of prostaglandins Pathologic prostate specimen weight and perioperative outcomes in LRP
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: bone mineral density, Diagnosis, genistein, LRP, obesity, outcomes, prostaglandin, prostate weight, PSA levels, risk, soy | Leave a Comment »
This morning’s news reports address: Prostate cancer risk and obesity (again) Italian experience with HIFU at a median follow-up of about 2 years The prognostic value of a 5-year PSA value <0.2 ng/ml in men treated with brachytherapy (with or without EBRT and/or hormones) Proposed European guidelines on the need to remove the seminal vesicles [...]
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: BMI, brachytherapy, EBRT, HIFU, Italy, obesity, picoplatin, Poniard, seminal vesicles | Leave a Comment »
A recent epidemiologic study in King County, Washington, has found an increased risk for prostate cancer associated with statin use among obese men.
Filed under: Prevention | Tagged: cancer, news, obesity, prostate, statin, update | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site